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SHORT COMMUNICATION
The polyoxyethylene castor oil Cremophor EL modifies multidrug
resistance
G.J. Schuurhuis, H.J. Broxterman, H.M. Pinedo, Th. H.M. van Heijningen, C.K. van Kalken,
J.B. Vermorken, E.C. Spoelstra & J. Lankelma
Department ofMedical Oncology, Free University Hospital, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
In vitro the presence of P-glycoprotein is associated with the
possibility to reverse multidrug resistance (MDR) with com-
pounds with different structural features (Bradley et al.,
1988). Although many such compounds have been described,
only a few can be expected to be active at clinically
achievable concentrations: quinidine (Tsuruo et al., 1984),
amiodarone (Chauffert et al., 1987), bepridil (Schuurhuis et
al., 1987) and cyclosporin A (Slater et al., 1986; Twentyman,
1988) are examples. During our investigations on the in vitro
effects of resistance modifiers on daunorubicin and vincristine
accumulation in freshly obtained human tumour cells
(Schuurhuis et al., 1989b) we found that Cremophor EL,
which is a polyethoxylated castor oil used as a solubiliser,
e.g. of vitamins and of the immunosuppressant drug cyclo-
sporin A, had effects on drug accumulation similar to other
resistance modifiers used. In order to study whether this
effect of Cremophor EL was related to MDR, we inves-
tigated the effects of Cremophor EL on anthracycline
accumulation and anthracycline and vincristine cytotoxicity
in MDR and sensitive model cell lines and we compared the
results with those obtained using cyclosporin A and
verapamil. Both human squamous lung cancer cells (SW-
1573, Keizer et al., 1989; Broxterman et al., 1989) and
human myeloma cells (8226, Dalton et al., 1986, 1989b) were
used. The latter ones are of special interest because of the
increased in vivo sensitivity ofmyeloma to a regimen contain-
ing vincristine, doxorubicin and dexamethasone (the VAD
regimen) when verapamil is used as a modifier (Dalton et al.,
1989a). Both types of MDR cells overexpress P-glycoprotein
(Dalton et al., 1989b; Kuiper et al., 1990).
Cells were cultured in Dulbecco's modified minimal essen-
tial medium supplemented with 10% fetal bovine serum
(Gibco, Paisley, Scotland). The human multiple myeloma
8226Dox4 and 8226Dox40 cells were cultured in the presence
of 40 and 400 nM doxorubicin (Adriablastina, Farmitalia,
Milan, Italy) respectively. SW-1573/2R160 cells were derived
from SW-1573/2R50 cells (Keizer et al., 1989; Broxterman et
al., 1989) by continuous exposure to 160 nM doxorubicin.
Experiments were performed on cells cultured for 1-2 weeks
without doxorubicin. Cells were allowed to adhere (SW-1573
cells) or equilibrate in suspension (8226 cells) in six-well
tissue culture plates (Costar, Cambridge, MA, USA). Then
they were incubated under 5% CO2 with doxorubicin or
vincristine sulfate (Sigma Chemical Co., St Louis, MO, USA)
with or without resistance modifiers for at least three cell
doubling times. Cell doubling times were 22 h (SW-1573),
45h (SW-1573/2R160), 36h (8226S), 42h (8226Dox4) and
44 h (8226Dox40). Thereafter the cells were counted as des-
cribed by Schuurhuis et al. (1987) using a Sigmex microcell
counter model CC-I 10. With high concentrations of Cremo-
phor EL (>132 jg ml') or when fresh human plasma was
used, the cells were co-incubated with doxorubicin and Crem-
ophor EL for 2 h, post-incubated for 2 h with Cremophor
EL only and further incubated in fresh medium as described
above. Resistance modifiers used were verapamil.HCI (Sig-
ma), cyclosporin A (Sandoz AG, Basel, Switzerland), cyclo-
sporin A in Cremophor EL (Sandimmune, Sandoz, AG) and
Cremophor EL (Sandoz AG). Cyclosporin A in Cremophor
EL was used because in this form (Sandimmune) cyclosporin
A is administered clinically. The choice of the concentration
of the modifiers used in the cytotoxicity experiments in this
study is based on other in vitro studies: 1-2I1M cyclosporin
A and 4 tLM verapamil usually are effective in modulating
MDR (Durie & Dalton, 1988; further reviewed in Twen-
tyman, 1988 and Kaye, 1988). The choice of Cremophor EL
concentrations is based on the amounts present in the cyclo-
sporin A solutions which are administered in the clinic (as
Sandimmune), e.g. a final dilution of 2 gM cyclosporin A
contains 33 fig ml-' Cremophor EL.
Cellular accumulation and efflux experiments were per-
formed essentially as described earlier (Schuurhuis et al.,
1987). Some 0.1-0.3 x 106 cells were incubated for 2 h at
37C in 550jil Dulbecco's medium, pH 7.4, lacking NaHCO3
but containing 20 mM HEPES and 10% fetal bovine serum,
to which '4C-doxorubicin (Amersham Laboratories, Amer-
sham, UK) or '4C-daunorubicin (Amersham) was added with
or without resistance modifiers. The final concentration of
doxorubicin and daunorubicin was made 0.5 liM by adding
unlabelled doxorubicin and daunorubicin (Specia, Paris,
France). After two washes with ice-cold phosphate-buffered
saline, the cells were transferred to liquid scintillation fluid.
No corrections were made for direct binding of anthracyc-
lines to the cells since binding was the same whether or not
modifiers were present and was too low to affect the con-
clusions (5-20% at maximum). For efflux experiments sen-
sitive cells were incubated with 0.5 lSM doxorubicin or
daunorubicin. Resistant cells were incubated with 2.5 JAM
daunorubcin (SW-i 573/2R160) or 1 JiM doxorubicin
(8226Dox4); this resulted in about the same intracellular drug
amounts as in the sensitive cells in these experiments after 2 h
of incubation. After washing with ice-cold Dulbecco's
medium, the cells were resuspended in fresh ice-cold medium
and incubated for 1 h at 37°C. After washing the cell-
associated radioactivity was determined.
In Table I it is shown that Cremophor EL (132figml-')
partly reversed doxorubicin resistance in SW-1573/2R160
cells (the dose modifying factor, DMF, was 6.3; resistance
index = 77) while only a small effect was observed on the
parent cell line. With concentrations higher than 132 fig ml-I
higher dose modifying factors were found (> 10). At a con-
centration of 33 lg ml-' Cremophor EL had a small
although significant effect in SW-1573/2R160 cells
(DMF = 1.9, see Table I). Two JAM pure cyclosporin A had a
DMF of 8.3 ± 1.5 (mean ± s.d. in three experiments,
P<0.01), while 2 JM cyclosporin A (Sandimmune), which
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Table I Effect of resistance modifiers on doxorubicin cytotoxicity in human squamous lung cancer and
myeloma MDR and sensitive cells
DMP
IC50 (nM) CEL CEL Vp Vp
Cell line (control) (33 zgmt-') (132jgml-') Cycl. Al (4pM) (16 AM)
SW-1573 22±_3c 1.6±0.4c 1.8±0.6 1.4±0.2 1.5±0.1
SW-1573/2R160 1700±300[77]d 1.9±0.1' 6.3 ±0.1 16.8 ± 6.If 5.4±O..5 11.0 ± 1.4'
8226S 12 2 1.2 0.1 1.1 0.3 1.1 ± 0.1 1.4±0
8226Dox4 95 ± 12 [7.9] 5.4 ± 1.79 7.1 ± 1.2' 4.6 ± 0.2g 3.4 + 0.3 4.9 0.8g
8226Dox40 540 + 110 [45] 2.6 ± 1.3f 13.3 ± 2.8' 5.6 ± 2.2 - 8.4 + 2.7
Vp,verapamil; Cycl. A,cyclosporin A; CEL, CremophorEL;ICG, doxorubicinconcentration resultingin
50% growth inhibition. aDMF, dose modifying factor = IGC without resistance modifier/IC50 with
resistance modifier. bCycl. A (Sandimmune): 2 laM for SW-1573 cells, 1 gM for 8226 cells (2jAM cycl. A is
dissolved in 33 ,lg ml-' CEL and 1 jAM cycl.A in 16.5figml-' CEL). cValues are means ± s.d. from 2-5
independent experiments. dValues within brackets: IC50 MDR cell line/IC50 parent cell line. eSignificantly
different from I (P<0.05, Student's t test). fSignificantly different from 1 (P<0.02). gSignificantly different
from I (P<0.01).
contains 33 ytg ml-' Cremophor EL, had a DMF of 16.8
(Table I). These results show that both compounds as such
are able to sensitize SW-1573/2R160 cells to doxorubicin and
that the effects are additive when cyclosporin A is given as
Sandimmune.
Also in the human myeloma cell line 8226Dox40 with a
moderately high doxorubicin resistance index (45, see Table
I) Cremophor EL (33 fLg ml-') had only a small effect (DMF
of 2.6, see Table I). Like in SW-1573/2R160 cells, with higher
concentrations of Cremophor EL the effects on doxorubicin
cytotoxicity became more pronounced (Table I). On the
other hand, in 8226Dox4 cells with a low doxorubicin resis-
tance index (7.9, see Table I) 33 glg ml-' Cremophor EL
largely reversed doxorubicin resistance (Table I and Figure
1). One jAM cyclosporin A in Cremophor EL (16.5 yg ml-')
or verapamil (4 or 16pM) had no greater effect than
Cremophor EL (33 yg ml-') alone (Table I). Figure 1 shows
the dose - response relationship for Cremophor EL on dox-
orubicin cytotoxicity: even at concentrations of 4.1 and
8.2 lAg ml-' (which correspond to dilutions of 1:256,000 and
1:128,000 respectively), signifcant effects were observed.
These data show that in cells with low levels of MDR
reversal of resistance with cyclosporin A may have been
achieved at least partly due to the carrier (Cremophor EL)
effects alone. This may have important implications for the
design and interpretation of clinical trials with cyclosporin A
as reversing agent.
Interestingly, our results indicate that cells with
intermediate to high levels of resistance, like 8226Dox40 and
SW-1573/2R160 cells, may not be good models to predict the
possible clinical usefulness of resistance modifiers in P-
glycoprotein-containing tumours. This may be due to the fact
that drug efflux from cells with low amounts of P-
glycoprotein can be blocked more efficiently.
Drug accumulation experiments confirmed the findings
reported above. Cremophor EL significantly stimulated dox-
orubicin and daunorubicin accumulation in 8226Dox40 and
SW-1573/2R160 cells, respectively, but not in the sensitive
cells (Table II). In SW-1573/2R160 cells daunorubicin was
used instead of doxorubicin, since drug accumulation
differences between sensitive and resistant cells and impor-
tantly, effects of modifiers on drug accumulation in resistant
cells, were much more pronounced for daunorubicin than for
doxorubicin in these cells. Cremophor EL (132 jg ml-')
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Figure 1 Effect of Cremophor EL on doxorubicin cytotoxicity in
8226Dox4 and 8226S cells. Myeloma cells were incubated with
doxorubicin in the presence of increasing concentrations of
Cremophor EL (CEL) as described in the text. Symbols represent
means ± s.e. from 2-3 independent experiments, except CEL
(16.5 fig ml-') (one experiment). 8226Dox4: 0-0, control;
O 0, CEL (4.1 figml-'); A-A, CEL (8.2 jAgml-'); V-V,
CEL (16.5Sjgml-'; 0-0, CEL (33figml-'); O-*, CEL
(132 jg ml-'); x -x, Cycl. A (Sandimmune, 21AM). 8226S: 0---
*, control; *---*, CEL (33jLgml-'); x---x, Cycl. A (2jAM).
Table II Effect ofresistance modifiers on anthracycline accumulation and retention in human squamous lung cancer and
myeloma MDR and sensitive cells
anthracyclinea AEFb
accumulation Cel Cycl.A Vp Anthr.
Cell line (pmolper 106 cells) (132 ogmlh') (8jLM) (16jAM) retentionc REP
SW-1573 346±52' 0.99+0.08' 1.05±0.12 1.18±0.11' 63 12e 1.12±0.17
SW-1573/2R160 56 ± 8 [6.2]f 2.05 0.39h 4.39 ± 0.88h 3.09 0.45h 34 ± 8 1.37 ± 0.09'
8226S 147 17 0.94±0.19 1.05±0.18 0.99±0.11 72±5 0.98±0.04
8226Dox4 107 20 [1.4] 1.24 0.11h 1.34 0.16' 1.30 0.19h 67 9 1.08 0.05'
8226Dox40 84 1 [1.8] 1.27± 0.17h 1.54 0.26h 1.30 0.18' -
Abbreviations as in Table I. aDrug accumulation (2 h at 37°C) was carried out with 0.5gM daunorubicin for SW-1573 cells
andwith 0.5 jAM doxorubicinfor8226cells."AEF,accumulationenhancement factor = drugaccumulationwithmodifier/drug
accumulation without modifier. CAnthracycline retention was measured after 1 h ofdrugefflux; shown are means ( ± s.d.) of
initial amounts. dREF, retention enhancement factor = drug retention with CEL (1321g ml-')/drug retention without CEL.
'Values are means ± s.d. from 2-6 independent experiments each performed in triplicate. fValues between brackets: drug
accumulation in sensitivecells/drug accumulation in resistant cells. gSignificantly different from 1 (P<0.05, Student's ttest).
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creasing its retention in the MDR cells (Table II), as seems to
be the case for cyclosporin A (Nooter et al., 1989). No
significant effects of Cremophor EL on anthracycline reten-
tion were seen in the parent cells. The effects of the modifiers
on drug cytotoxicity in MDR cells seems to be due for an
important part to a change in intracellular drug distribution
instead of to stimulation of drug accumulation as will be
discussed later. In addition, stimulation of anthracycline
accumulation by modifiers occurs in a dose-dependent way
and therefore low concentrations of modifiers stimulate
anthracycline accumulation only slightly. In order to show
clearly that the resistance modifiers used stimulate drug
accumulation in our MDR cells we have chosen higher con-
centrations of modifiers for accumulation and retention
experiments than for cytotoxicity experiments.
We have also determined the effect of Cremophor EL on
vincristine cytotoxicity in 8226Dox4 cells since vincristine is
included in clinical protocols for myeloma patients. Figure 2
shows that Cremophor EL is active in reversing vincristine
resistance with dose modifying factors of 2.2, 3.2, 8.4 and
28.7 for the concentrations of 8.2, 16.5, 33 and 132ligmlh',
respectively. Since the resistance index was 15, this means a
more than complete reversal of resistance at 132figml-'.
Interestingly, the sensitive cells were affected too, although to
a limited extent (DMF: 2.2, see Figure 2). Two gM
verapamil, a concentration which is ony achievable clinically
with serious side-effects (Benson et al., 1985; Ozols et al.,
1987) was less effective than Cremophor EL at a concentra-
tion of 33yg ml-' (see Figure 2).
One major determinant of the efficacy of a drug in the
clinic can be its ability to bind to proteins (Koch-Weser &
Sellers, 1976). We have shown previously that an increase in
the protein concentration signifcantly decreased the potency
of resistance modifiers such as verapamil, bepridil, diltiazem
and Ro 11-2933/001 to stimulate anthracycline accumula-
tion in MDR cells (Broxterman et al., 1987). Table III shows
that Cremophor EL at concentrations of 33 and 132 figml-
largely retains its ability to reverse doxorubicin resistance in
8226Dox4 cells at a high protein concentration (compare
Tables I and III). At this protein concentration the dose
modifying factors of verapamil, even at a concentration of
16I1M, are somewhat lower than for Cremophor EL (Table
III). In addition, when 8226Dox4 cells were incubated in
fresh human plasma for 2 h with doxorubicin and
Cremophor EL (132 pg ml-'), followed by a 2 h post-
incubation in plasma with Cremophor EL only, the effect
was about the same as in control experiments using 10%
fetal bovine serum in the same incubation protocol (DMF of
2.5-3.5). These results indicate that proteins probably do not
strongly interfere with the capacity of Cremophor EL to
modulate MDR.
Despite the many studies addressing the mechanism of
action of resistance modifiers, the answers offered are not yet
satisfactory. Resistance modifiers seem to act at least partly
by binding to P-glycoprotein (Safa et al., 1986; Cornwell et
al., 1986; Foxwell et al., 1989) and competing for drug efflux
via P-glycoprotein (Bradley et al., 1988), thereby increasing
drug accumulation in the cell. As an alterntive some resis-












Figure 2 Effect of Cremophor EL on vincristine cytotoxicity in
8226Dox4 and 8226S cells. Cells were incubated with vincristine
in the presence or absence ofCremophor EL (CEL) or verapamil.
Each point represents mean ± s.e. of 2-4 independent experi-
ments. 8226Dox4: 0-O, control; 0-0, CEL (8.2 jgml-');
A-A, CEL (16.59lgml-'); V-V, CEL (33pgml-'); O-O,
CEL (1329Agml1'); U--U, verapamil (0.5I1M); A---A, verap-
amil (I 9AM); V---V, verapamil (2 9aM). 8226S: *---@, control;
*---*, CEL (1329fg ml ').
branes as reported for Tween 80 (Carlsen et al., 1976). We
have shown previously that the action of resistance modifiers
may be due largely to their effects on the intracellular drug
localisation instead of on drug accumulation: in cells with
high levels of MDR doxorubicin is present mainly in the
cytoplasm in the absence of resistance modifiers. However, in
the presence of resistance modifiers doxorubicin is mainly in
the nucleus, as is the situation in drug-sensitive cells (Willing-
ham et al., 1986; Schuurhuis et al., 1989a; Broxterman et al.,
1990). Cremophor EL also was able to produce a similar
change in drug localisation (from mainly cytoplasmic to
mainly nuclear) in SW-1573/2R160 cells as determined with
fluorescence microscopy (results not shown). These observa-
tions offer an explanation for the finding that modifiers such
as cyclosporin A are able to reverse drug resistance to a large
extent without strongly affecting drug accumulation (Slater et
al., 1986; Schuurhuis et al., 1989a; this study).
Since protein kinase C (PKC) activity has been associated
with MDR and its reversal (Aquino et al., 1988; Fine et al.,
1988; O'Brien et al., 1989; Ferguson & Cheng, 1987), it is of
interest that Cremophor EL, like other resistance modifiers
such as verapamil, tamoxifen, cyclosporin A and
phenothiazines (Mori et al., 1980; O'Brian et al., 1985;
Walker et al., 1989; Schatzman et al., 1981), strongly inhibits
PKC activity at concentrations comparable to those used in
this study (Zhao et al., 1989).
In conclusion, our findings demonstrate that Cremophor
EL is a potent modifier of MDR in human myeloma cells at
protein concentrations which closely mimic the in vivo situa-
tion. Clinical studies in myeloma with Cremophor EL as a
resistance modifier thus seem warranted. Further, Cremophor
Table III Reversal of doxorubicin resistance in 8226 MDR cells in protein-richa
medium
DMFO
IC50 (nM) CEL CEL Vp Vp
Cell line (control) (33 lAgml-') (132,Agml') 4"AM 16gM
8226S 26.3 5.9c 1.0 0.1 - 1.2 0.3
8226Dox4 250 + 71 [9.5]d 5.5 ± 0.7e 6.2 + 1.f 2.0 + 0.7 3.5 ± 0.7'
Abbreviations asinTableI.aThegrowth medium contained4% bovine serumalbumin
(Sigma) in addition to 10% fetal calf serum. bDMF, dose modifying factor: IC50 minus
resistance modifier/IC", plus resistance modifier. cValues are means ± s.d. from 2-3
experiments. dValues between brackets: IC,o 8226Dox4 cells/ICM, 8226S cells.
'Significantly different from I (P<0.05, Student's t test). 'Signficantly different from I
(P<0.02).594 G.J. SCHUURHUIS et al.
EL may turn out to be useful in the treatment of other
P-glycoprotein-containing tumours in addition to myeloma
since we have found that in vitro the compound was active
on other P-glycoprotein-containing human MDR cancer cells
like squamous lung cancer cells (this paper) and ovarian
cancer cells (submitted) as well as intrinsically resistant P-
glycoprotein-containing human colon cancer cells (submit-
ted).
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